Northern Trust’s KalVista Pharmaceuticals KALV Stock Holding History

Northern Trust’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.32M	Buy	363,694 +11,721	+3%	+$189K	﹤0.01%	2249
2025 Q4	$5.68M	Buy	351,973 +1,250	+0.4%	+$16.6K	﹤0.01%	2399
2025 Q3	$4.27M	Sell	350,723 -1,429	-0.4%	-$19.7K	﹤0.01%	2592
2025 Q2	$3.98M	Sell	352,152 -35,410	-9%	-$433K	﹤0.01%	2590
2025 Q1	$4.47M	Buy	387,562 +21,392	+6%	+$218K	﹤0.01%	2482
2024 Q4	$3.1M	Sell	366,170 -13,205	-3%	-$137K	﹤0.01%	2783
2024 Q3	$4.39M	Buy	379,375 +46,680	+14%	+$587K	﹤0.01%	2562
2024 Q2	$3.92M	Buy	332,695 +14,827	+5%	+$173K	﹤0.01%	2529
2024 Q1	$3.77M	Sell	317,868 -8,628	-3%	-$115K	﹤0.01%	2643
2023 Q4	$4M	Buy	326,496 +51,278	+19%	+$467K	﹤0.01%	2633
2023 Q3	$2.65M	Buy	275,218 +13,602	+5%	+$139K	﹤0.01%	2785
2023 Q2	$2.35M	Buy	261,616 +25,503	+11%	+$235K	﹤0.01%	2927
2023 Q1	$1.86M	Sell	236,113 -5,850	-2%	-$43.7K	﹤0.01%	2972
2022 Q4	$1.64M	Sell	241,963 -2,733	-1%	-$14.6K	﹤0.01%	3094
2022 Q3	$3.55M	Buy	244,696 +478	+0.2%	+$6.68K	﹤0.01%	2695
2022 Q2	$2.4M	Sell	244,218 -3,458	-1%	-$38.1K	﹤0.01%	2955
2022 Q1	$3.65M	Sell	247,676 -7,233	-3%	-$104K	﹤0.01%	2769
2021 Q4	$3.37M	Buy	254,909 +21,169	+9%	+$337K	﹤0.01%	2943
2021 Q3	$4.08M	Sell	233,740 -8,093	-3%	-$164K	﹤0.01%	2863
2021 Q2	$5.79M	Buy	241,833 +13,163	+6%	+$344K	﹤0.01%	2750
2021 Q1	$5.88M	Sell	228,670 -574	-0.3%	-$15.1K	﹤0.01%	2655
2020 Q4	$4.35M	Sell	229,244 -9,652	-4%	-$166K	﹤0.01%	2762
2020 Q3	$3.01M	Sell	238,896 -3,297	-1%	-$41.2K	﹤0.01%	2842
2020 Q2	$2.93M	Buy	242,193 +52,910	+28%	+$563K	﹤0.01%	2823
2020 Q1	$1.45M	Buy	189,283 +3,514	+2%	+$47.4K	﹤0.01%	3031
2019 Q4	$3.31M	Buy	185,769 +7,248	+4%	+$94.6K	﹤0.01%	2829
2019 Q3	$2.07M	Buy	178,521 +104,691	+142%	+$1.69M	﹤0.01%	3087
2019 Q2	$1.64M	Buy	73,830 +32,930	+81%	+$772K	﹤0.01%	3169
2019 Q1	$1.17M	Buy	40,900 +172	+0.4%	+$3.73K	﹤0.01%	3304
2018 Q4	$805K	Buy	40,728 +10,034	+33%	+$202K	﹤0.01%	3432
2018 Q3	$678K	Buy	+30,694	New	+$415K	﹤0.01%	3572
2016 Q4	–	Sell	-1,467	Closed	-$9K	–	4198
2016 Q3	$9K	Hold	1,467	–	–	﹤0.01%	4140
2016 Q2	$13K	Sell	1,467 -7,618	-84%	-$88.2K	﹤0.01%	4147
2016 Q1	$82K	Sell	9,085 -1	-0%	-$18	﹤0.01%	3944
2015 Q4	$461K	Hold	9,086	–	–	﹤0.01%	3532
2015 Q3	$454K	Buy	9,086 +7,003	+336%	+$597K	﹤0.01%	3520
2015 Q2	$209K	Buy	+2,083	New	+$207K	﹤0.01%	3775

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust's KALV Position: Q1 2026 in Review

Northern Trust increased its KalVista Pharmaceuticals (KALV) stake by 3.3% in Q1 2026, buying an estimated $189K and bringing the position to 363,694 shares worth $7.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

Northern Trust first reported a position in KALV in Q2 2015 and has held it in 37 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Northern Trust held 363,694 shares of KalVista Pharmaceuticals worth $7.32M as of Q1 2026.
Northern Trust bought 11,721 KalVista Pharmaceuticals shares in Q1 2026, an estimated $189K.
KalVista Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2249 holding.
Northern Trust first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 37 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.